Trial reportRheumatology (Oxford, England)2025
A multivariable prediction model to identify anti-CCP positive people in those with non-specific musculoskeletal symptoms in primary care.
Trial report in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Targeted anti-CCP testing to identify people at risk of rheumatoid arthritis in primary care: an early economic evaluation.Rheumatology advances in practice · 2026Article
- Identifying people at risk of rheumatoid arthritis in primary care: a qualitative study.The British journal of general practice : the journal of the Royal College of General Practitioners · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesWe aimed to develop a prediction model identifying people presenting to primary care with musculoskeletal symptoms likely to be anti-CCP positive and therefore at risk of developing RA.
methodsParticipants aged ≥16 years, with new-onset non-specific musculoskeletal symptoms and no history of clinical synovitis, completed a symptom questionnaire and had an anti-CCP test. Model development used LASSO-penalized logistic regression, performance was assessed using area under the receiver operating characteristic curve (AUROC) and decision curve analysis, model over-fit was estimated using bootstrapping and cross-validation. Participants were followed-up at 12 months for RA or seronegative/undifferentiated inflammatory arthritis diagnosis.
resultsAnalysis included 6879 participants; 203 (2.95%) of whom were anti-CCP positive. Eleven predictors were retained: male sex, first-degree relative with RA, ever smoked and joint pain in: back, neck, shoulders, wrists, hands/fingers, thumbs, knees, feet/toes. AUROC was 0.65 (95% CI 0.61, 0.69, optimism = 0.03). Using a 4% decision threshold, the model recommended an anti-CCP test in 1288 (18.7%) participants, 78 (6.1%) of whom were anti-CCP positive, compared with 125/5591 (2.2%) below the threshold. Net benefit was 0.0040 (0.0020 corrected). Forty-eight participants were diagnosed with inflammatory arthritis/RA within 12 months. Of those who were above the threshold and anti-CCP positive, 32.1% developed inflammatory arthritis/RA compared with 0.4% of those who were anti-CCP negative. Of those below the threshold, 0.3% were diagnosed with inflammatory arthritis/RA.
conclusionsTargeted anti-CCP testing in primary care may aid earlier identification of people at risk of RA, prompting specialist referral to rheumatology for earlier diagnosis and initiation of disease-modifying therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.